MEDPHealthcare · Diagnostics & ResearchThe 14 Wall Street analysts covering Medpace Holdings, Inc. hold a median 12-month price target of $609 — +0.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Medpace Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (98): The business earns solid, repeatable profits on what it owns.
Value (66): The shares cost a lot relative to the profits and assets behind them.
Size (11): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MEDP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +0.8% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2026 | UBS | Upgrade | Neutral | $405 → $673 |
| 24 July 2026 | Baird | Maintains | Neutral | $547 → $624 |
| 24 July 2026 | Baird | Maintains | Neutral | — |
| 24 July 2026 | BMO Capital | Maintains | Market Perform | $400 → $600 |
| 24 July 2026 | BMO Capital | Maintains | Market Perform | — |
| 24 July 2026 | Mizuho | Maintains | Outperform | $586 → $665 |
| 24 July 2026 | Mizuho | Maintains | Outperform | — |
| 24 July 2026 | RBC Capital | Maintains | Outperform | $484 → $692 |
| 24 July 2026 | RBC Capital | Maintains | Outperform | — |
| 24 July 2026 | TD Cowen | Maintains | Hold | $419 → $492 |
| 24 July 2026 | TD Cowen | Maintains | Hold | — |
| 24 July 2026 | Truist Securities | Maintains | Hold | $462 → $609 |
| 24 July 2026 | Truist Securities | Maintains | Hold | — |
| 13 July 2026 | Mizuho | Maintains | Outperform | — |
| 13 July 2026 | Mizuho | Maintains | Outperform | $495 → $586 |
| 8 July 2026 | Baird | Downgrade | Neutral | — |
| 8 July 2026 | Baird | Downgrade | Neutral | $477 → $547 |
| 7 July 2026 | Jefferies | Downgrade | Hold | $490 → $515 |
| 7 July 2026 | Jefferies | Downgrade | Hold | — |
| 24 Apr 2026 | Baird | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MEDP appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, Medpace Holdings, Inc. returned +13.6% against +17.7% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 20% of US stocks
Cheaper than 3% of US stocks
Cheaper than 10% of US stocks
Higher than 66% of US stocks
Higher than 68% of US stocks
Higher than 32% of US stocks
Higher than 80% of US stocks
Higher than 80% of US stocks
Higher than 98% of US stocks
Higher than 99% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Medpace Holdings, Inc. has a market value of $16.7B and an enterprise value of $16.4B.
Revenue in the twelve months to 30 June 2026: $2.8B. The latest quarter grew 17.2% year on year.
Net income over the same four quarters: $491.5M, a 17.7% net margin.
Diluted earnings per share, trailing twelve months: $17.06.
Free cash flow in the twelve months to 30 June 2026: $706.7M.
Medpace Holdings, Inc. spent $299.3M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 36.1×; forward P/E: 31.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Medpace Holdings, Inc. employs 6,500 people — $428K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Medpace Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Medpace (MEDP) ended the recent trading session at $602.90, down 2.84% from the prior day's close. The headline notes that the broader market improved.
Why it matters — The session's decline relative to an improving market is relevant to investors tracking MEDP's recent trading performance.
Medpace (MEDP) closed at $622.11 in the latest trading day, representing a 1% increase from the preceding session. The stock rose even as the broader market experienced a dip.
Why it matters — A MEDP watcher would note that the stock gained while the market declined, indicating relative strength in the share price during a down day for the broader market.
Zacks Investment Research published a comparison article examining whether Concentra Group (CON) or Medpace (MEDP) is the better value stock for investors at this time. The piece frames the two Medical Services stocks as competing value options.
Why it matters — Medpace watchers would care because the article assesses how MEDP stacks up against a peer on value-investing criteria, which may influence how investors view the stock.
Medpace Holdings, Inc. announced it will report its third quarter 2026 financial results after market close on Wednesday, October 21, 2026, and will host a conference call the following morning, Thursday, October 22, 2026, at 9:00 a.m. ET, with advance registration required for participation.
Why it matters — This announcement sets the date and timing for MEDP's next quarterly earnings disclosure and conference call, which investors and analysts will watch closely.
Medpace (MEDP) closed its recent trading session at $624.20, a +1.94% gain from the prior day's close, outperforming the broader market. The move reflects the stock's relative strength during that trading day.
Why it matters — MEDP watchers would note the stock's outperformance versus the broader market as a sign of relative trading momentum on that session.
The 14 Wall Street analysts covering Medpace Holdings, Inc. have a median 12-month price target of $609, with estimates ranging from $370 to $692. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Medpace Holdings, Inc., 2 rate it a Buy, 11 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Medpace Holdings, Inc. 96 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Medpace Holdings, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +0.8% from the last close, and Ticker Nerd's factor model ranks Medpace Holdings, Inc. 96 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Medpace Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MEDP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $370 to $692 over the next 12 months.
Medpace Holdings, Inc. returned +13.6% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Medpace Holdings, Inc. is a global clinical research organization that provides outsourced clinical development services for biotechnology, pharmaceutical, and medical device companies.
The most recent item we track (Zacks Investment Research, 6 Oct 2026): "Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors". Medpace (MEDP) ended the recent trading session at $602.90, down 2.84% from the prior day's close. The headline notes that the broader market improved.
Medpace Holdings, Inc. is a global clinical research organization that provides outsourced clinical development services for biotechnology, pharmaceutical, and medical device companies. Medpace supports the full clinical trial lifecycle, from Phase I through Phase IV, with services that include study design, project management, clinical monitoring, regulatory affairs, data management, biostatistics, medical writing, pharmacovigilance, and post-marketing support. The company also offers specialized laboratory and trial support capabilities such as central laboratory services, bioanalytical testing, imaging core laboratory services, and cardiac safety assessments. Medpace serves clients across North America, Europe, Asia, South America, Africa, and Australia, playing a central role in helping sponsors run complex clinical programs and advance medical products through development.
CEO Dr. August James Troendle M.D. · 6,500 employees · United States · https://www.medpace.com
